---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-114213"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2024-10-11T23:59:59+00:00"
generated_at: "2026-05-30T15:31:48.122166+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Acrivon doses first patient in Phase 1 trial of WEE1/PKMYT1 inhibitor ACR-2316

## Summary
- First patient dosed two quarters ahead of original timeline for ACR-2316 Phase 1 trial in solid tumors.
- ACR-2316 advanced from initial lead to Phase 1 in 15 months using AP3 platform.
- Initial clinical data from monotherapy dose optimization expected in 2H 2025.
- Trial assesses safety, tolerability, MTD, RP2D, PK, and anti-tumor activity per FDA Project Optimus.

## SEC filing metadata
- accession: 0000950170-24-114213
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2024-10-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000095017024114213/0000950170-24-114213-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000095017024114213/acrv-20241011.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-114213
- JSON: https://secwatch.observer/filing/0000950170-24-114213.json
- Plain text: https://secwatch.observer/filing/0000950170-24-114213.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.